JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, ti

Tweet Author

Tweet Content

JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/ppuzIB4iRf

What we need in very early arthritis It's easy to think that in our current world that we've done it all for rheumatoid

Tweet Author

RheumNow

Tweet Content

What we need in very early arthritis It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all https://t.co/v8T3JQwuhM

Korean Health claims data study of 35,133 newly Dx, seropositive #RA pts (2011 to 2020) & 1,386 (3.9%) were Dx w/ ne

Tweet Author

RheumNow

Tweet Content

Korean Health claims data study of 35,133 newly Dx, seropositive #RA pts (2011 to 2020) & 1,386 (3.9%) were Dx w/ new-onset stroke (CVA). Signif. lower risk of CVA w/ SSZ (aOR: 0.79) or HCQ (aOR: 0.83), but Increased risk w/ glucocorticoids (aOR: 1.71) & tocilizumab (aOR: 3.47) https://t.co/rPaj6cH74K

Using Veterans Affairs data (2006 - 2020) on RA-ILD patients, a target emulation trial showed no difference in mortality

Tweet Author

RheumNow

Tweet Content

Using Veterans Affairs data (2006 - 2020) on RA-ILD patients, a target emulation trial showed no difference in mortality or respiratory hospitalization comparing RA-ILD Rx w/ either RTX, abatacept, tocilizumab, tofacitinib. Does this mean? they Dont Work or the Do Work? https://t.co/MkQmKsE3WQ

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excite

Tweet Author

RheumNow

Tweet Content

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. https://t.co/tgfsU3uFVo

25 June 2025

A Review of Intracranial GCA

A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.

A systematic review included 102 studies and 340 patients with icGCA. The median age was 73.7 years with 47% patients being female.

post hoc MRI study from Osteoarthritis Initiative (OAI) of 210 knee OA pts (mean age 64) Rx w/ either IA corticosteroids

Tweet Author

RheumNow

Tweet Content

post hoc MRI study from Osteoarthritis Initiative (OAI) of 210 knee OA pts (mean age 64) Rx w/ either IA corticosteroids or hyaluronate (HA). Bboth reduced pain post-injx (WOMAC -5.2 CS & -2.1 HA), CS had worse progression (cartilage, BM lesions, meniscus) vs controls & HA https://t.co/pbb1ePXob1

Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) ?

Tweet Author

RheumNow

Tweet Content

Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN 3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/3qg1FWzZRI

Links

Lupus Nephritis Treatment Advances: New Therapies on the Horizon Promise Better… https://buff.ly/eaO00Ug

Lichenoid rash vs SCLE? JAMA Dermatology case - 60yoM w/ https://t.co/xl11CwB1AJ problems & meds has pink-red papul

Tweet Author

RheumNow

Tweet Content

Lichenoid rash vs SCLE? JAMA Dermatology case - 60yoM w/ https://t.co/xl11CwB1AJ problems & meds has pink-red papules (central hypopigmentation) on arms, chest, back (no fungus). Bx= lichenoid dermatitis. Rash worsened, red & annular; Dx now SCLE +ANA/Ro/La) from diltiazem. SCLE

Links

http://mult.med

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases During the Late-Breaking Abstract sess

Tweet Author

RheumNow

Tweet Content

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases During the Late-Breaking Abstract session at EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). https://t.co/5bjyaqTqSN https://t.co/i4mGMYfyNK

Links

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic disease… https://buff.ly/mLu5f8w

Topics

JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, ti

What we need in very early arthritis It's easy to think that in our current world that we've done it all for rheumatoid

Korean Health claims data study of 35,133 newly Dx, seropositive #RA pts (2011 to 2020) & 1,386 (3.9%) were Dx w/ ne

Using Veterans Affairs data (2006 - 2020) on RA-ILD patients, a target emulation trial showed no difference in mortality

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excite

post hoc MRI study from Osteoarthritis Initiative (OAI) of 210 knee OA pts (mean age 64) Rx w/ either IA corticosteroids

Upcoming Lupus Nephritis Pipeline 1. Gazyva (obinutuzumab) – due for FDA/EMA decision 2. Saphnelo IV (anifrolumab) ?

Lichenoid rash vs SCLE? JAMA Dermatology case - 60yoM w/ https://t.co/xl11CwB1AJ problems & meds has pink-red papul

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases During the Late-Breaking Abstract sess

Do you get our email newsletter?